AB1225 ASSOCIATION BETWEEN BONE METABOLISM MARKERS AND INCREASES IN BONE MINERAL DENSITY IN PATIENTS...
AB1225 ASSOCIATION BETWEEN BONE METABOLISM MARKERS AND INCREASES IN BONE MINERAL DENSITY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH ROMOSOZUMAB
About this item
Full title
Author / Creator
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
Osteoporosis is a metabolic bone disorder characterized by a systemic impairment of bone mass and microarchitecture that results in fragility fractures [1]. Romosozumab (Rmab), a humanized monoclonal anti-sclerostin antibody, increases bone mineral density (BMD) and decreases fragility fractures in patients with postmenopausal osteoporosis (PMO) [2...
Alternative Titles
Full title
AB1225 ASSOCIATION BETWEEN BONE METABOLISM MARKERS AND INCREASES IN BONE MINERAL DENSITY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH ROMOSOZUMAB
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2824646218
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2824646218
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.5854
